Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415991 | 0.83 | CYP11B1 (0.35) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL14464732 | 0.83 | CYP11B1 (0.35) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL9587793 | 0.83 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL8803490 | 0.83 | CYP11B1 (0.43) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL31646315 | 0.82 | CYP11B1 (0.38) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL7254443 | 0.82 | SIRT2 (0.38) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL3959113 | 0.82 | SIRT2 (0.40) | CYP11B1CYP11B2SIRT2 | |
| SCHEMBL1039275 | 0.80 | CYP11B1 (0.41) | CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL9587597 | 0.79 | SIRT2 (0.38) | TAAR1CYP11B1CYP11B2SIRT2ENPP2 | |
| SCHEMBL4025463 | 0.78 | CYP11B1 (0.39) | CYP11B1CYP11B2SIRT2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2041132-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003766-A2 | 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | TAAR1 1639/4885CYP11B1 20/4885CYP11B2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.